Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry

E-ISSN： 1873-5592|12|6|774-782

ISSN： 1389-4501

Source： Current Drug Targets, Vol.12, Iss.6, 2011-01, pp. : 774-782

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Public Perceptions of the Pharmaceutical Industry and Drug Safety: Implications for the Pharmacovigilance Professional and the Culture of Safety

By Olsen Axel K.

Drug Safety, Vol. 32, Iss. 10, 2009-10 ,pp. : 805-810

Adis International

Access to resources Recommend Favorite

Challenges in Pediatric Drug Development: A Pharmaceutical Industry Perspective

By Rose Klaus

Pediatric Drugs, Vol. 11, Iss. 1, 2009-01 ,pp. : 57-59

Adis International

Access to resources Recommend Favorite

Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective

Current Pharmaceutical Design, Vol. 15, Iss. 9, 2009-03 ,pp. : 957-965

Bentham Science Publishers

Access to resources Recommend Favorite

Drug-induced mitochondrial dysfunction in cardiac and skeletal muscle injury

By Sardo Vilma A Pereira Sandro L Oliveira Paulo J

Expert Opinion on Drug Safety, Vol. 7, Iss. 2, 2008-03 ,pp. : 129-146

Informa Healthcare

Access to resources Recommend Favorite

Data Safety Monitoring Boards: Their Role in Drug Development and Pharmaceutical Trials

By Boardman H.

International Journal of Pharmaceutical Medicine, Vol. 17, Iss. 1, 2003-01 ,pp. : 39-46

Adis International

Access to resources Recommend Favorite